1Stone N J,Robinson J,Lichtenstein AH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coil Cardiol,2013,(13):06028-06022.
2Kolata G. Experts reshape treatment guide for cholesterol[N].New York Tim es,2013.
3Smith SC,Benjamin E J,Bonow RO. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease:2011 update:a guideline from the American Heart Association and American College of Cardiology Foundation.Circulation[J].{H}Journal of the America College of Cardiology,2011,(22):2458-2473.
6Shang Q,Liu Z,Chen K. A systematic review of Xuezhikang,an extract from red yeast rice,for coronary heart disease complicated by dyslipidemia[J].{H}Evidence-based Complementary and Alternative Medicine,2012.636547.
7Feng Y,Xu H,Chen K. Natural polypill Xuezhikang:its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions[J].{H}JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE,2012,(4):318-328.
3Go AS,Mozaffarian D, Roger VL,et at. Heart dis-ease and stroke statistics~2013 update: a reportfrom the American Heart Association[ J ]. Circula-tion, 2013,127(1): e6 -e245.
4Salomon JA, Vos T, Hogan DR, et al. Commonvalues in assessing health outcomes from dis-ease and injury: disability weights measurementstudy for the Global Burden of Disease Study2010[J]. Lancet, 2012,380(9859): 2129 -2143.
5Moran A,Gu D,Zhao D,et al. Future cardiovas-cular disease in china: markov model and riskfactor scenario projections from the coronaryheart disease policy model in China[J]. Circ Car-diovasc Qual Outcomes, 2010,3(3): 243 -252.
6Ji JF, Pan EC, Li JX, et al. Classical risk factorsof cardiovascular disease among Chinese malesteel workers: a prospective cohort study for 20years [J]. BMC Public Health, 2011,11: 497.
7Friedemann C, Heneghan C, Mahtani K, et al.Cardiovascular disease risk in healthy childrenand its association with body mass index : sys-tematic review and meta-analysis [J]. BMJ,2012,345: e4759.
6Holbrook A, wright M, Sung M, et al. statin-associated rhabdomyolysis: is there a dose-response relationship. Can J Cardiol, 2011, 27 (2) : 146-151.
7Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf, 2010, 33 (3):171- 187.
8Kones R. The Jupiter study, CRP screening, and aggressive statintheraphyimplications for the primary prevention of cardiovascular disease[J].Ther Adv Cardiovasc Dis,2009,3(4):309-315.
